Denis Biju-Duval

deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium.

Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium.

Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg.

Saladax Biomedical, Inc. develops novel and commercializes diagnostic assays for the practical delivery of personalized medicine. Its products include pipeline, MY5-FU, mypaclitaxel, and mydocetaxel. MyCare product serves the central nervous system field, with antipsychotic drug dose management assays. The company was founded by Adrienne Choma and Salvatore J. Salamone in 2004 and is headquartered in Bethlehem, PA.

Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany.

PamGene BV provides biopharmaceutical products and clinical settings. It also provides PamChip biomarkers, such as tyrosine kinases, serine/threonine kinases, nuclear receptors, and reagent kits. The firm provides BioNavigator, a software tool for interpretation of PamChip measurements, as well as for performing data analysis for various PamChip experiments; and Evolve that enables data capture and analysis, as well as for the export of data into third party software formats. The company was founded by Tim Kievits in December 1999 and is headquartered in 's-Hertogenbosch, the Netherlands.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.

Pacira Cryotech, Inc. develops novel technologies for treatment of peripheral nerves. Its iovera treatment harnesses the power of cold with the Focused Cold Therapy delivery system and delivers immediate results for both therapeutic and aesthetic applications. The firm’s iovera treatment does not use toxins, chemicals, or pharmaceuticals to achieve results and leaves nothing behind in the body. The company was founded by Lisa Elkins in 2005 and is headquartered in Fremont, CA.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA.

Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015.

Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands.

Erasmus MC operates as an academic hospital. It is affiliated with the Erasmus University of Rotterdam, and home to its faculty of medicine. It has special units such as Neurosurgery, Cardiograph surgery, Neonatal and pediatric surgery and intensive care, Pediatric oncology and Level I trauma center. The company was founded in 2002 and is headquartered in Rotterdam, Netherlands.

Novigenix SA develops molecular diagnostics for cancer. The firm specializes in new generation liquid biopsy tests for early detection of cancer and precision medicine. The company was founded by Sahar Hosseinian in 2014 and is headquartered in Epalinges, Switzerland.

Destina Genomics Ltd. is engaged in development of molecular diagnostic products. Its products include pipeline assay kits and liverace. The company was founded by Hugh Llyine, Juan J. Diaz-Mochon and Mark Bradley in 2011 and is headquartered in Edinburgh, the United Kingdom.

Saving Patients' Lives Medical BV develops and manufactures nano-sized iron oxide particles for effective diagnostics of cancer metastasis. The company was founded by Ari Aminetzah and Patrik Zamecnik in 2015 and is headquartered in Nijmegen, the Netherlands.

Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

Sogam SA is an investment holding Belgian company founded in 1964. The private company is based in Brussels, Belgium. Sogam functions as an investment holding company.

Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium.

The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.